iPSC-derived cerebral organoids from Alzheimer’s disease (AD) patients show hallmark tau pathology, which is reduced by alpha and beta secretase inhibitors, thus providing a platform for testing anti-AD drugs [225]. Here, MAPT is linked to Alzheimer disease.